BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 27713152)

  • 1. Detection of cellular senescence within human invasive breast carcinomas distinguishes different breast tumor subtypes.
    Cotarelo CL; Schad A; Kirkpatrick CJ; Sleeman JP; Springer E; Schmidt M; Thaler S
    Oncotarget; 2016 Nov; 7(46):74846-74859. PubMed ID: 27713152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of Cellular Senescence Reveals the Existence of Senescent Tumor Cells within Invasive Breast Carcinomas and Related Metastases.
    Cotarelo CL; Schad A; Schmidt M; Hönig A; Sleeman JP; Thaler S
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update.
    Tang P; Tse GM
    Arch Pathol Lab Med; 2016 Aug; 140(8):806-14. PubMed ID: 27472239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
    Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
    Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?
    Wang X; Stolla M; Ring BZ; Yang Q; Laughlin TS; Rothberg PG; Skinner K; Hicks DG
    Hum Pathol; 2016 Sep; 55():196-201. PubMed ID: 27246177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters.
    Hashmi AA; Hashmi KA; Irfan M; Khan SM; Edhi MM; Ali JP; Hashmi SK; Asif H; Faridi N; Khan A
    BMC Res Notes; 2019 Sep; 12(1):605. PubMed ID: 31547858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Senescence Markers During Mammalian Embryonic Development.
    Storer M; Keyes WM
    Methods Mol Biol; 2017; 1534():199-210. PubMed ID: 27812881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of Ki-67 antigen expression between luminal A and triple-negative subtypes of breast cancer.
    Borges US; Costa-Silva DR; da Silva-Sampaio JP; Escórcio-Dourado CS; Conde AM; Campelo V; Gebrim LH; da Silva BB; Lopes-Costa PV
    Med Oncol; 2017 Sep; 34(9):156. PubMed ID: 28780646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
    Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
    Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki-67 is a prognostic marker for hormone receptor positive tumors.
    Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
    Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
    Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
    Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
    Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
    Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogene-induced senescence: a double edged sword in cancer.
    Liu XL; Ding J; Meng LH
    Acta Pharmacol Sin; 2018 Oct; 39(10):1553-1558. PubMed ID: 29620049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.
    Cuadros M; Cano C; López FJ; López-Castro R; Concha A
    Pathobiology; 2013; 80(1):32-40. PubMed ID: 22832278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.
    Angelini PD; Zacarias Fluck MF; Pedersen K; Parra-Palau JL; Guiu M; Bernadó Morales C; Vicario R; Luque-García A; Navalpotro NP; Giralt J; Canals F; Gomis RR; Tabernero J; Baselga J; Villanueva J; Arribas J
    Cancer Res; 2013 Jan; 73(1):450-8. PubMed ID: 23288917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
    Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
    J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.